For research and educational purposes only. Not medical advice.
Cagrilintide Reference
Educational, not medical advice reference for Cagrilintide: Metabolic, Fat Loss; regulatory status, evidence posture, source review, and schedule notes. Also…
Reference summary
Phase 2 cagrilintide-monotherapy data have been published. pepSmart displays cagrilintide only as trial-context educational content.
- Categories
- Metabolic, Fat Loss
- Aliases
- AM833, Long-acting amylin analog (solo)
- Evidence posture
- human — Human trial data exist, but cagrilintide remains investigational — no FDA-approved drug label and no approved monotherapy product.
- Regulatory status
- Investigational. Cagrilintide is a long-acting amylin analog developed by Novo Nordisk and is studied solo and in fixed-dose combination with semaglutide (CagriSema). There is no FDA-approved cagrilintide-only drug label.
- Content review status
- investigational verified